Ipatasertib clinical trials
Also written GDC-0068 and RG7440.
ClinicalTrials.gov finds 57 studies for ipatasertib. How that becomes 53 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives ipatasertib. Its counts are asked again every night. How drug pages count
- 57Found by its intervention search · See all 57 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 54 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 57Give ipatasertib to participants
- −4Give it beside what is tested
- 53Test it: the count on this site
Get an email when these change. Save the ipatasertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
53 studies that test it; most in 2021 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 10 |
| 2022 | 5 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 28 · Other 25
Hoffmann-La Roche (16) · Genentech, Inc. (12) · National Cancer Institute (NCI) (7) · Queen Mary University of London (2) · Canadian Cancer Trials Group (2) · Massachusetts General Hospital (1) · Royal Marsden NHS Foundation Trust (1) · Institute of Cancer Research, United Kingdom (1)
Often tested with
Tested in the same studies.
Atezolizumab (9) · Inavolisib (8) · Bevacizumab (7) · Paclitaxel (6) · Ado-Trastuzumab Emtansine (5) · Cobimetinib (5) · Carboplatin (4) · Pertuzumab (4)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test ipatasertib.
- Jan 2027Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersPhase 1/2 · National Cancer Institute (NCI)
- Feb 2027Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialPhase 2 · National Cancer Institute (NCI)
- Jun 2027Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionPhase 2 · Royal Marsden NHS Foundation Trust
- Jun 2027Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckPhase 2 · National Cancer Institute (NCI)
- Jul 2027Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerPhase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses ipatasertib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 53
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05172245Dose found, added to chemoradiation for head and neck cancerWritten as IpatasertibReport a problem
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Continued for people from earlier Roche studiesWritten as IpatasertibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005With atezolizumab in one breast cancer platform armWritten as IpatasertibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759In one combination arm of a breast cancer platform studyWritten as IpatasertibReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352With atezolizumab in one endometrial cancer cohortWritten as IpatasertibReport a problem
- Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line ImmunotherapyRecruitingPhase 2Jun Zhang, MD, PhDNCT04467801With docetaxel after immunotherapy in lung cancerWritten as IpatasertibReport a problem
- Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05276973Dose found, added to neoadjuvant paclitaxel and carboplatin in ovarian cancerWritten as IpatasertibReport a problem
- Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05172258Added to pembrolizumab in first-line head and neck cancerWritten as IpatasertibReport a problem
- Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05538897Added to megestrol acetate in endometrioid endometrial cancerWritten as IpatasertibReport a problem
- Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06400251Alone in tumours with AKT mutations, MATCH subprotocol Z1KWritten as IpatasertibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060In AKT-mutant tumours, one MATCH subprotocolWritten as IpatasertibReport a problem
- Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast CancerCompletedPhase 1/2City of Hope Medical CenterNCT03853707Dose found with carboplatin, paclitaxel or capecitabine and atezolizumabWritten as IpatasertibReport a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342In one biomarker-selected arm for rare ovarian tumoursWritten as IpatasertibReport a problem
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845In one AKT-altered cohort of a tumour-agnostic platformWritten as IpatasertibReport a problem
- Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05554380With paclitaxel in PTEN/AKT-altered non-breast tumoursWritten as IpatasertibReport a problem
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Active, not recruitingPhase 1Massachusetts General HospitalNCT03959891With endocrine therapy, with or without palbociclib, in HR-positive breast cancerWritten as IpatasertibReport a problem
- Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedPhase 2Hospices Civils de LyonNCT04739202With atezolizumab in one personalised gastric cancer armWritten as Atezolizumab + IpatasertibReport a problem
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698Added to atezolizumab in one lung cancer platform armWritten as IpatasertibReport a problem
- Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCActive, not recruitingPhase 2Queen Mary University of LondonNCT05498896Added to neoadjuvant chemotherapy and atezolizumab in triple-negative breast cancerWritten as IpatasertibReport a problem
- Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionActive, not recruitingPhase 2Royal Marsden NHS Foundation TrustNCT04920708Added to fulvestrant and a CDK4/6 inhibitor when ctDNA persistsWritten as Ipatasertib 300mgReport a problem
See all 53 studies that test ipatasertib →
Tested on its own · 7 — no other medicine in its arm
- Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line ImmunotherapyRecruitingPhase 2Jun Zhang, MD, PhDNCT04467801With docetaxel after immunotherapy in lung cancerWritten as IpatasertibReport a problem
- Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06400251Alone in tumours with AKT mutations, MATCH subprotocol Z1KWritten as IpatasertibReport a problem
- A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.CompletedPhase 1Hoffmann-La RocheNCT04341259Blood levels and safety in Chinese patientsWritten as IpatasertibReport a problem
- A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT03341884Blood levels with liver impairmentWritten as IpatasertibReport a problem
- Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy SubjectsCompletedPhase 1Genentech, Inc.NCT02536391Formulation and food effect in healthy volunteersWritten as Ipatasertib (capsule)Report a problem
- A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy VolunteersCompletedPhase 1Genentech, Inc.NCT02063581Capsule against tablet in healthy volunteersWritten as ipatasertib (Capsule)Report a problem
- A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid TumorsCompletedPhase 1Genentech, Inc.NCT01090960First-in-human dose escalation in refractory solid tumoursWritten as GDC-0068Report a problem
Tested with established drugs · 19 — they are given beside it
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05172245Dose found, added to chemoradiation for head and neck cancerWritten as IpatasertibReport a problem
- Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05172258Added to pembrolizumab in first-line head and neck cancerWritten as IpatasertibReport a problem
- Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05538897Added to megestrol acetate in endometrioid endometrial cancerWritten as IpatasertibReport a problem
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Active, not recruitingPhase 1Massachusetts General HospitalNCT03959891With endocrine therapy, with or without palbociclib, in HR-positive breast cancerWritten as IpatasertibReport a problem
- Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCActive, not recruitingPhase 2Queen Mary University of LondonNCT05498896Added to neoadjuvant chemotherapy and atezolizumab in triple-negative breast cancerWritten as IpatasertibReport a problem
- Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionActive, not recruitingPhase 2Royal Marsden NHS Foundation TrustNCT04920708Added to fulvestrant and a CDK4/6 inhibitor when ctDNA persistsWritten as Ipatasertib 300mgReport a problem
- Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorActive, not recruitingPhase 3Canadian Cancer Trials GroupNCT04650581Added to fulvestrant after a CDK4/6 inhibitor and aromatase inhibitorWritten as IpatasertibReport a problem
- Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer PatientsCompletedPhase 1SOLTI Breast Cancer Research GroupNCT04253561With pertuzumab and trastuzumab in PIK3CA-mutant HER2-positive breast cancerWritten as IpatasertibReport a problem
- Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate CancerCompletedPhase 3Hoffmann-La RocheNCT03072238Added to abiraterone against placebo in prostate cancer, phase 3Written as IpatasertibReport a problem
- A Trial of Ipatasertib in Combination With AtezolizumabActive, not recruitingPhase 1/2Institute of Cancer Research, United KingdomNCT03673787Dose escalated with atezolizumab in PI3K-active tumoursWritten as ipatasertibReport a problem
- A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerTerminatedPhase 1Hoffmann-La RocheNCT04060862Added to palbociclib and fulvestrant against placeboWritten as IpatasertibReport a problem
- A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedPhase 1Hoffmann-La RocheNCT03800836With atezolizumab and paclitaxel in triple-negative breast cancerWritten as IpatasertibReport a problem
- Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast CancerCompletedPhase 2MedSIRNCT04464174With non-taxane chemotherapy in pretreated triple-negative breast cancerWritten as IpatasertibReport a problem
- A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast CancerCompletedPhase 3Hoffmann-La RocheNCT03337724Added to paclitaxel in PIK3CA/AKT1/PTEN-altered breast cancerWritten as IpatasertibReport a problem
- A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.CompletedPhase 1Hoffmann-La RocheNCT03840200Dose found with rucaparib in breast, ovarian and prostate cancerWritten as IpatasertibReport a problem
- A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction CancerCompletedPhase 2Genentech, Inc.NCT01896531Added to FOLFOX against placebo in gastric cancerWritten as IpatasertibReport a problem
- A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal ReceptorsCompletedPhase 2Genentech, Inc.NCT02162719Added to paclitaxel against placebo in triple-negative breast cancerWritten as IpatasertibReport a problem
- A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast CancerCompletedPhase 2Genentech, Inc.NCT02301988Added to paclitaxel before surgery in triple-negative breast cancerWritten as IpatasertibReport a problem
- A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on IpatasertibCompletedPhase 1Hoffmann-La RocheNCT03222310How itraconazole changes its blood levelsWritten as IpatasertibReport a problem
Tested in a combination · 27 — another drug in the study is under test too
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Continued for people from earlier Roche studiesWritten as IpatasertibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005With atezolizumab in one breast cancer platform armWritten as IpatasertibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759In one combination arm of a breast cancer platform studyWritten as IpatasertibReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352With atezolizumab in one endometrial cancer cohortWritten as IpatasertibReport a problem
- Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05276973Dose found, added to neoadjuvant paclitaxel and carboplatin in ovarian cancerWritten as IpatasertibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060In AKT-mutant tumours, one MATCH subprotocolWritten as IpatasertibReport a problem
- Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast CancerCompletedPhase 1/2City of Hope Medical CenterNCT03853707Dose found with carboplatin, paclitaxel or capecitabine and atezolizumabWritten as IpatasertibReport a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342In one biomarker-selected arm for rare ovarian tumoursWritten as IpatasertibReport a problem
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845In one AKT-altered cohort of a tumour-agnostic platformWritten as IpatasertibReport a problem
- Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05554380With paclitaxel in PTEN/AKT-altered non-breast tumoursWritten as IpatasertibReport a problem
- Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedPhase 2Hospices Civils de LyonNCT04739202With atezolizumab in one personalised gastric cancer armWritten as Atezolizumab + IpatasertibReport a problem
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698Added to atezolizumab in one lung cancer platform armWritten as IpatasertibReport a problem
- Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT05180006Added to atezolizumab in a short window before breast surgeryReport a problem
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedPhase 1/2Hoffmann-La RocheNCT03280563With atezolizumab, with or without fulvestrant, in platform armsWritten as IpatasertibReport a problem
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT03385655In one biomarker-selected prostate cancer armWritten as IpatasertibReport a problem
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992Alone or combined in AKT- or PTEN-altered arms of a basket studyWritten as IpatasertibReport a problem
- CRAFT: The NCT-PMO-1602 Phase II TrialCompletedPhase 2German Cancer Research CenterNCT04551521In one molecularly matched arm for rare cancersWritten as IpatasertibReport a problem
- Pre-operative Immunotherapy Combination Strategies in Breast CancerCompletedPhase 2Queen Mary University of LondonNCT03395899Added to atezolizumab before breast cancer surgeryWritten as IpatasertibReport a problem
- A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedPhase 3Hoffmann-La RocheNCT04177108Added to atezolizumab and paclitaxel in triple-negative breast cancerWritten as IpatasertibReport a problem
- Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate CancerTerminatedPhase 1/2David VanderWeeleNCT04737109With darolutamide and androgen deprivation before prostate surgeryWritten as IpatasertibReport a problem
Showing 20 of 27. See all 27 →
One option of several · 4 — a test or a strategy chooses among drugs
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377One drug in the combinations the screening assignsWritten as IpatasertibReport a problem
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingPhase 2German Cancer Research CenterNCT05332561One genomics-guided option after neoadjuvant breast cancer therapyWritten as IpatasertibReport a problem
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedPhase 2Hoffmann-La RocheNCT03498521One option chosen by genomic profiling in unknown primary cancerWritten as IpatasertibReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One targeted option in a strategy compared with standard careWritten as IpatasertibReport a problem
Codes
What other systems call ipatasertib · ClinicalTrials.gg INT006352
- MeSH (NLM) C583616ipatasertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 524Y3IB4HQIPATASERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27078088ipatasertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91072IpatasertibOne source FDA
- DrugBank DB11743One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583616 | ipatasertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 524Y3IB4HQ | IPATASERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27078088 | ipatasertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91072 | Ipatasertib | One source FDA |
| DrugBank | DB11743 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.